{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:30:38Z","timestamp":1766068238740,"version":"3.48.0"},"reference-count":11,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pan Afr Med J"],"abstract":"<jats:p>There is a lack of studies describing the impact of mpox in non-HIV immunosuppressed conditions such as severe autoimmune disorders, haematologic malignancies, solid organ transplant recipients, and those on immunosuppressive medications. Here, we report a case of mpox in a 52-year-old female with background diabetes mellitus and rheumatoid arthritis on 18 months of immunosuppressive drugs (prednisolone and methotrexate) who presented to an mpox treatment center at the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria with disseminated febrile rash syndrome and a history of sexual exposure with a heterosexual partner with a febrile rash. Monkeypox virus (MPXV) and varicella-zoster virus (VZV) DNA levels in lesional swabs were quantified by qPCR, which returned positive and negative, respectively. Genomic sequencing was performed, and clade 2b was identified as the infecting clade of the virus. She was seronegative to HIV 1 and 2 (ELISA). Despite having a high burden of skin rash (&gt;500 lesions), confluent skin distribution, and systemic complications, she essentially recovered on supportive treatment, highlighting her reduced net state of immunosuppression. This case report of mpox in a Nigerian lady with background immunosuppression successfully managed by a multidisciplinary team underscores the need for proactive screening and timely management of mpox to prevent unfavorable outcomes. Further studies are needed to understand the burden and outcome of mpox in the non-HIV immunosuppressive population.<\/jats:p>","DOI":"10.11604\/pamj.supp.2025.50.1.46082","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:25:06Z","timestamp":1766067906000},"source":"Crossref","is-referenced-by-count":0,"title":["Mpox in a non-HIV immunosuppressed host: a case report from Nigeria"],"prefix":"10.11604","author":[{"given":"Chizaram","family":"Onyeaghala","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chioma","family":"Tochukwu-Onyejieme","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uche","family":"Tralagba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolaji Ibiesa","family":"Otike-Odibi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omosivie","family":"Maduka","sequence":"additional","affiliation":[{"name":"Department of Community of Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Datonye","family":"Alasia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4870","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"ref0","unstructured":"Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y et al. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019 Aug;19(8):872-9. PubMed | Google Scholar"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tar\u00edn-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Su\u00f1er C, Ant\u00f3n A et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. The Lancet. 2022 Aug 27;400(10353):661-9. PubMed | Google Scholar","DOI":"10.1016\/S0140-6736(22)01436-2"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Mmerem JI, Umenzekwe CC, Johnson SM, Onukak AE, Chika-Igwenyi NM, Chukwu SK et al. Mpox and Chickenpox Coinfection: Case Series From Southern Nigeria. J Infect Dis. 2024 Mar 26;229(Supplement_2):S260-4, 6. PubMed | Google Scholar","DOI":"10.1093\/infdis\/jiad556"},{"key":"ref3","unstructured":"CDC. Clinical Considerations for Mpox in Immunocompromised People. Accessed November 26, 2024."},{"key":"ref4","unstructured":"Mitj\u00e0 O, Alemany A, Marks M, Mora JIL, Rodr\u00edguez-Aldama JC, Silva MST et al. Mpox in people with advanced HIV infection: a global case series. The Lancet. 2023 Mar 18;401(10380):939-49. PubMed | Google Scholar"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Dohms JE, Saif YM. Guest editorial: Criteria for evaluating immunosuppression. Avian Dis. 1984 Apr-Jun;28(2):305-10. PubMed | Google Scholar","DOI":"10.2307\/1590336"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ahmed SK, Mohamed MG, Dabou EA, Abuijlan I, Chandran D, El-Shall NA et al. Monkeypox (mpox) in immunosuppressed patients. F1000Res. 2023 Feb 2;12:127. PubMed | Google Scholar","DOI":"10.12688\/f1000research.130272.1"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ogoina D, Dalhat MM, Denue BA, Okowa M, Chika-Igwenyi NM, Oiwoh SO et al. Mpox Epidemiology and Risk Factors, Nigeria, 2022. Emerg Infect Dis. 2024 Sep;30(9):1799-808. PubMed | Google Scholar","DOI":"10.3201\/eid3009.240135"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ogoina D, Dalhat MM, Denue BA, Okowa M, Chika-Igwenyi NM, Yusuff HA et al. Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study. Lancet Infect Dis. 2023 Dec;23(12):1418-1428. PubMed | Google Scholar","DOI":"10.1016\/S1473-3099(23)00427-9"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ogoina D, Iroezindu M, James HI, Oladokun R, Yinka-Ogunleye A, Wakama P et al. Clinical Course and Outcome of Human Monkeypox in Nigeria. Clin Infect Dis. 2020 Nov 5;71(8):e210-4. PubMed | Google Scholar","DOI":"10.1093\/cid\/ciaa143"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Sethi Y, Agarwal P, Murli H, Waheed S, Matar SG, Baklola M et al. Neuropsychiatric manifestations of monkeypox: A clinically oriented comprehensive review. Brain Behav. 2023 Feb 27;13(4):e2934. PubMed | Google Scholar","DOI":"10.1002\/brb3.2934"}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:25:09Z","timestamp":1766067909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/series\/50\/1\/6\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":11,"URL":"https:\/\/doi.org\/10.11604\/pamj.supp.2025.50.1.46082","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"46082"}}